In 2017, LEO Pharma helped more than 80 million patients, increased revenues by 8% in local currencies, and generated revenues at more than DKK 10bn for the first time in the company’s 110 year old history. Earnings before interest and tax (EBIT) more than doubled to DKK 852 million despite significant investments in new products.
LEO Pharma’s revenue increased by DKK 700 million, or 8% in local currencies, to DKK 10,481 million, compared to 2016. EBIT more than doubled to DKK 852 million.
The company’s operating profit before depreciation and amortisation was above expectations going from DKK 1,346 million in 2016 to DKK 2,005 million in 2017. The operating profit improvements were mainly driven by realised cost savings from efficiency projects launched in 2016, and the full-year effect of sales from Astellas’ global dermatology portfolio, which LEO Pharma acquired in 2016.
Read the full story in the annual results press release' to the right . Annual Reports are listed below.